U.S. Markets closed

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.7600-0.0300 (-1.68%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7900
Open1.7800
Bid1.7500 x 800
Ask1.7900 x 1800
Day's Range1.7100 - 1.7900
52 Week Range0.5600 - 4.1300
Volume125,242
Avg. Volume375,242
Market Cap95.587M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-0.4480
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.60
  • GlobeNewswire

    Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

    ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.About Clearside BiomedicalClearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com.Investor and Media Contacts: Jenny Kobin Remy Bernarda ir@clearsidebio.com (678) 430-8206Source: Clearside Biomedical, Inc.

  • Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020

    ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2020 financial results will be reported on Monday, August 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 2290836.About Clearside BiomedicalClearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com.Investor and Media Contacts: Jenny Kobin Remy Bernarda ir@clearsidebio.com (678) 430-8206Source: Clearside Biomedical, Inc.